An additional analysis of the efficacy and safety of therapy in the Russian population of patients with multiple sclerosis participated in phase III international multicenter clinical trials: results of alemtuzumab study

Boyko A.N.

doi:https://doi.org/10.17116/jnevro2019119102147

Boyko A.N.

N.I. Pirogov Russian National Research Medical University;
Federal Center for Cerebrovascular Pathology and Stroke

SPIN RSCI: 9921-9109
Scopus AuthorID: 7102247663
ORCID: 0000-0002-2975-4151

An additional analysis of the efficacy and safety of therapy in the Russian population of patients with multiple sclerosis participated in phase III international multicenter clinical trials: results of alemtuzumab study

Authors:

Boyko A.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(10‑2): 147‑152

DOI: 10.17116/jnevro2019119102147

Read: 1457 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Boyko AN. An additional analysis of the efficacy and safety of therapy in the Russian population of patients with multiple sclerosis participated in phase III international multicenter clinical trials: results of alemtuzumab study. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(10‑2):147‑152. (In Russ.)
https://doi.org/10.17116/jnevro2019119102147

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Quality assessment of health care delivery to patients with sexually transmitted infections in dermatovenereological institutions of Moscow according to medical records analysis. Russian Journal of Clinical Dermatology and Venereology. 2024;(5):503-509

Psoriasis in pregnant women. Russian Journal of Clinical Dermatology and Venereology. 2024;(5):517-524

Low-level laser therapy in multiple sclerosis: justification and optimization methods of application. (Literature review). Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(5):45-56

Tuberculous otitis media in an adolescent. Clinical case. Russian Bulletin of Otorhinolaryngology. 2024;(5):63-66

Glial fibrillary acidic protein: is there a relationship with the course of multiple sclerosis and traumatic brain injury before the onset of multiple sclerosis?. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):80-84

An individual approach to the diagnosis and treatment of an acute psychotic condition in a patient with a multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):97-102

Surgical treatment of secondary trigeminal neuralgia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):203-209

Comparative analysis of the results of treatment of gastric polyps by methods of loop electroexcision, laser and endoscopic polypectomy with aspiration capture. Endoscopic Surgery. 2024;(6):24-30

Black Acanthosis: Diagnosis and Treatment Issues. Russian Journal of Clinical Dermatology and Venereology. 2024;(6):709-712

Quality of life of patients with multiple sclerosis in the Smolensk region. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):36-40

Abstract:

The article is discussing the data of additional analyses of subpopulation of MS patients from Russia, participating in phase III clinical trials of DMTs (article by E.P. Evdoshenko et al in this issue). This review the data of alemtuzumab trials CARE-MS I and CARE-MS II with special attention to Russian patients. Such statistics allows to find new peculiarities of the drug effectiveness, selection of groups of patients, showing better results in MS patients with high disease activity, but low residual disability. Data of longitudinal observations are of special interest. Presented data on the 8-years observation of MS after alemtuzumab therapy show low annual relapse rate (mean 0,14—0,18) and stable disability levels, even with confimed disability improvement of EDSS in 41—47% of patients.

Keywords:

multiple sclerosis

treatment

alemtuzumab

longitudinal observation

Authors:

Boyko A.N.

N.I. Pirogov Russian National Research Medical University;
Federal Center for Cerebrovascular Pathology and Stroke

SPIN RSCI: 9921-9109
Scopus AuthorID: 7102247663
ORCID: 0000-0002-2975-4151

Close metadata

References:

Gusev EI, Zavalishin IA, Boyko AN, Zakcharova MN. Demyelinating diseases of the central nervous system. Neurology’. National Manual Book. Eds. Gusev E.I., Konovalov A.N., Skvortsova V.I. M.: GEOTAR-Media; 2018. (In Russ.)
Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263-1273. https://doi.org/10.1016/S0140-6736(18)30475-6
Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R; GALA Study Group. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol. 2013;73(6):705-713. https://doi.org/10.1002/ana.23938
Lashch NYu, Boiko AN. Glatiramer acetate: A review of the results of GALA and GLACIER clinical studies. Neurology, Neuropsychiatry, Psychosomatics. 2016;8(2):117-120. (In Russ.) https://doi.org/10.14412/2074-2711-2016-2-117-120
Hartung HP, Aktas O, Boyko AN. Alemtuzumab: anew therapy for active relapsing-remitting multiple sclerosis. Mult Scler. 2015;21(1):22-34. https://doi.org/10.1177/1352458514549398
Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA; CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1819-1828. https://doi.org/10.1016/S0140-6736(12)61769-3
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1829-1839. https://doi.org/10.1016/S0140-6736(12)61768-1
Khan O, Rieckmann P, Boyko A, Selmaj K, Ashtamker N, Davis MD, Kolodny S, Zivadinov R. Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study. Mult Scler. 2017;23(6):818-829. https://doi.org/10.1177/1352458516664033
Pelletier D, Arnold DL, Boyko AN, Comi G, Hartung HP, Kubala Havrdova E, Inshas JS, McCombes P, Nakamura K, Oreja-Guevara C, Pazzilli C, Selmaj K, Scott TF, Chung L, Daizadeh N, Afsar S, Van Wijmeersch B. Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study) (May 4—10). Philadelphia, PA, USA: Presented at 71st Annual Meeting of the American Academy of Neurology (AAN). 2019.
Singer BA, Alroughani R, Broadley S, Eichau S, Hartung H, Kubala Havrdova E, Ho Jin Kim, Nakamura K, Navas C, Pozzilli C, Rovira A, Vermersch P, Wray S, Chung L, Daizadeh N, Afsar S, Selmaj KW. Alemtuzumab Controlled Clinical and MRI Outcomes and Slowed Brain Volume Loss in RRMS Patients: 8-year Follow-up of CARE-MS II Patients (TOPAZ study) (February 28—March 2). Dallas, TX, USA: Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum. 2019.
Alifirova VI, Bisaga GN, Boyko AN, Bryukhov VV, Davydovskaya MV, Zakharova MN, Zakharova EV, Malkova NA, Popova EV, Salogub GN, Sivertseva SA, Troshina EA, Khachanova NV, Schmidt TE. Clinical recommendations on the use of alemtuzumab (lemtrada). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017;117(2-2):115-126. (In Russ.) https://doi.org/10.17116/jnevro201711722115-126